Glutathione
Also called: GSH, reduced glutathione, L-glutathione
Glutathione (GSH) is a tripeptide described as the most abundant endogenous antioxidant and a regulator of oxidative stress and immune function. Supplements provide reduced glutathione by mouth; trials have also studied glutathione applied to the skin and given intravenously.
- Category
- Amino acid and protein
- Forms
- Reduced glutathione (oral tablets, capsules, orally dissolving film); topical and intravenous glutathione are also studied
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 2 Moderately studied in people. A 2025 systematic review describes five RCTs of oral glutathione versus placebo for skin lightening, plus topical studies and one placebo-controlled intravenous study; it reports no pooled estimate in its abstract. Separate oral RCTs studied cystic fibrosis, obese men and healthy adults. [1]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BSkin and hair1 topic
CSeveral areas, whole body or blood2 topics
CBlood sugar and weight1 topic
CCancer1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Skin lightening (melanin index) in healthy people | B | A 2025 systematic review describes five RCTs and one open-arm study in which oral glutathione (250-500 mg/day) reduced melanin index versus placebo; it judged topical and oral effects moderate and not sustained. [1] |
| Body glutathione stores in healthy adults | C | A 6-month RCT in 54 non-smoking adults found oral glutathione (250 or 1,000 mg/day) raised blood, erythrocyte, plasma and lymphocyte glutathione; levels returned to baseline after a 1-month washout. [3] |
| Insulin sensitivity in obese men with or without type 2 diabetes | C | A 3-week double-blind RCT in 20 men found whole-body insulin sensitivity increased with 1,000 mg/day glutathione; markers of oxidative stress did not change. [4] |
| Growth in children with cystic fibrosis | C | A 24-week multicenter placebo-controlled RCT (58 children aged 2-10 completing) found no difference in weight-for-age, weight or BMI, or in inflammatory markers. [5] |
| Chemotherapy-induced peripheral neuropathy | C | A 2026 network meta-analysis (25 RCTs of glutathione, its boosters and other agents) found no agent reduced all-grade neuropathy; glutathione was associated with less grade 3/4 neuropathy, not retained in double-blind-only analyses. [6] |
Main constituents: Glutathione (GSH), a tripeptide antioxidant [3]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Oral glutathione skin-lightening trials used 250 mg once a day, 250 mg twice a day and 500 mg once a day. [1]
- A 6-month trial of body stores used 250 or 1,000 mg/day. [3]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications4 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- A 2025 systematic review concluded that intravenous glutathione is contraindicated for skin lightening because of lack of efficacy and side effects. [1]
- In children with cystic fibrosis, oral glutathione for 24 weeks was safe and well tolerated. [5]
- A 2019 systematic review of skin effects reported some adverse events, none serious. [2]
Identity, quality and standardization
- In a crossover study in healthy adults, an orally dissolving film produced higher plasma glutathione at 4 and 6 hours than tablets after a single 300 mg dose. [7]
Regulatory status
- US: FDA had no questions about GRAS Notice 293 for glutathione as an ingredient in conventional foods such as beverages, cereals and dairy products at 5 to 742.5 mg per serving (closed December 22, 2009). [8]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [9]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Glutathione (GSH, reduced form), described as the most abundant endogenous antioxidant Amino acids, amines and peptides (tripeptide) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 4 entries naming glutathione, alone, as an L-cysteine-glutathione mixed disulfide, or in combinations (earliest NDI 425 submitted 2006-10-30; most recent NDI 1099 submitted 2018-11-08). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P5]
- FDA's GRAS Notice Inventory lists GRN 293 (glutathione; a resubmission of GRN 244): FDA had no questions about its use in conventional foods at 5 to 742.5 mg per serving (closed December 22, 2009). [P4]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P8]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- In a 6-month RCT in 54 adults, oral glutathione 1,000 mg/day raised mean glutathione 30-35% in erythrocytes, plasma and lymphocytes and 260% in buccal cells; 250 mg/day raised blood and erythrocyte levels 17% and 29%. [P1]
- A 2019 systematic review notes that the clinical efficacy of oral glutathione is questioned because of its limited absorption and bioavailability. [P2]
Formulations studied to change absorption
Human data only.
- After a single 300 mg dose in healthy adults, an orally dissolving film gave significantly higher plasma glutathione at 4 and 6 h than a tablet, with a longer Tmax and a trend toward higher Cmax and iAUC0-6h. [P3]
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr 2015;54(2):251-263 (PMID 24791752), 2014-05-05. pubmed.ncbi.nlm.nih.gov
- Dilokthornsakul W, et al. The clinical effect of glutathione on skin color and other related skin conditions: a systematic review. J Cosmet Dermatol 2019;18(3):728-737 (PMID 30895708), 2019-03-20. pubmed.ncbi.nlm.nih.gov
- Jung ES, et al. Formulation-dependent differences in systemic glutathione availability: comparative pharmacokinetics of orally dissolving film and tablet formulations in healthy adults. Eur J Pharm Biopharm 2026;226:115174 (PMID 42392376), 2026-07-02. pubmed.ncbi.nlm.nih.gov
- U.S. FDA. GRAS Notice Inventory: GRN No. 293, Glutathione (resubmission of GRN 244), 2009-12-22. hfpappexternal.fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142, 2026-10-30. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
Sources
- Sarkar R, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol 2025;64(6):992-1004 (PMID 39444151), 2024-10-23. pubmed.ncbi.nlm.nih.gov
- Dilokthornsakul W, et al. The clinical effect of glutathione on skin color and other related skin conditions: a systematic review. J Cosmet Dermatol 2019;18(3):728-737 (PMID 30895708), 2019-03-20. pubmed.ncbi.nlm.nih.gov
- Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr 2015;54(2):251-263 (PMID 24791752), 2014-05-05. pubmed.ncbi.nlm.nih.gov
- Søndergård SD, et al. The effects of 3 weeks of oral glutathione supplementation on whole body insulin sensitivity in obese males with and without type 2 diabetes: a randomized trial. Appl Physiol Nutr Metab 2021;46(9):1133-1142 (PMID 33740389), 2021-03-19. pubmed.ncbi.nlm.nih.gov
- Bozic M, et al. Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial. J Pediatr Gastroenterol Nutr 2020;71(6):771-777 (PMID 32960827), 2020-12. pubmed.ncbi.nlm.nih.gov
- Geum MJ, et al. Evidence on Glutathione and Boosters for Prevention of Chemotherapy-Induced Neuropathy: A Systematic Review and Network Meta-Analysis. Basic Clin Pharmacol Toxicol 2026;139(5):e70319 (PMID 42876024), 2026-11. pubmed.ncbi.nlm.nih.gov
- Jung ES, et al. Formulation-dependent differences in systemic glutathione availability: comparative pharmacokinetics of orally dissolving film and tablet formulations in healthy adults. Eur J Pharm Biopharm 2026;226:115174 (PMID 42392376), 2026-07-02. pubmed.ncbi.nlm.nih.gov
- U.S. FDA. GRAS Notice Inventory: GRN No. 293, Glutathione (resubmission of GRN 244), 2009-12-22. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in amino acid and protein: 5-HTP (5-hydroxytryptophan) · Beta-alanine · BPC-157 · Branched-chain amino acids (BCAAs) · Carnosine (L-carnosine) · Collagen peptides · Creatine · L-arginine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.